Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.

Wang D, Yang Y, Jiang L, Wang Y, Li J, Andreasen PA, Chen Z, Huang M, Xu P.

J Med Chem. 2019 Feb 28;62(4):2172-2183. doi: 10.1021/acs.jmedchem.8b01908. Epub 2019 Feb 15.

PMID:
30707839
2.

Origin and diversification of the plasminogen activation system among chordates.

Chana-Muñoz A, Jendroszek A, Sønnichsen M, Wang T, Ploug M, Jensen JK, Andreasen PA, Bendixen C, Panitz F.

BMC Evol Biol. 2019 Jan 17;19(1):27. doi: 10.1186/s12862-019-1353-z.

3.

Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217.

Xu M, Chen Y, Xu P, Andreasen PA, Jiang L, Li J, Huang M.

FEBS Lett. 2018 Aug;592(15):2658-2667. doi: 10.1002/1873-3468.13191. Epub 2018 Jul 30.

4.

Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.

Jiang L, Oldenburg E, Kromann-Hansen T, Xu P, Jensen JK, Andreasen PA, Huang M.

Biochim Biophys Acta Gen Subj. 2018 Sep;1862(9):2017-2023. doi: 10.1016/j.bbagen.2018.06.016. Epub 2018 Jun 27.

PMID:
29959058
5.

Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation.

Kromann-Hansen T, Lange EL, Lund IK, Høyer-Hansen G, Andreasen PA, Komives EA.

PLoS One. 2018 Feb 8;13(2):e0192661. doi: 10.1371/journal.pone.0192661. eCollection 2018.

6.

Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.

Xu P, Andreasen PA, Huang M.

Int J Biol Sci. 2017 Sep 21;13(10):1222-1233. doi: 10.7150/ijbs.21597. eCollection 2017. Review.

7.

Multi-tissue RNA-seq and transcriptome characterisation of the spiny dogfish shark (Squalus acanthias) provides a molecular tool for biological research and reveals new genes involved in osmoregulation.

Chana-Munoz A, Jendroszek A, Sønnichsen M, Kristiansen R, Jensen JK, Andreasen PA, Bendixen C, Panitz F.

PLoS One. 2017 Aug 23;12(8):e0182756. doi: 10.1371/journal.pone.0182756. eCollection 2017.

8.

Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved.

Jendroszek A, Sønnichsen MS, Muñoz AC, Leyman K, Christensen A, Petersen SV, Wang T, Bendixen C, Panitz F, Andreasen PA, Jensen JK.

Thromb Haemost. 2017 Aug 30;117(9):1688-1699. doi: 10.1160/TH17-02-0102. Epub 2017 Aug 3.

PMID:
28771275
9.

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.

Kromann-Hansen T, Louise Lange E, Peter Sørensen H, Hassanzadeh-Ghassabeh G, Huang M, Jensen JK, Muyldermans S, Declerck PJ, Komives EA, Andreasen PA.

Sci Rep. 2017 Jun 13;7(1):3385. doi: 10.1038/s41598-017-03457-7.

10.

A Conjugate of Two tPA-Binding RNA Aptamers Efficiently Inhibits Fibrinolysis.

Bjerregaard N, Dupont DM, Andreasen PA.

Nucleic Acid Ther. 2017 Apr;27(2):95-104. doi: 10.1089/nat.2016.0637. Epub 2017 Jan 4.

PMID:
28051346
11.

An RNA Aptamer Inhibits a Mutation-Induced Inactivating Misfolding of a Serpin.

Madsen JB, Andersen LM, Dupont DM, Trelle MB, Johansen JS, Jensen JK, Jørgensen TJ, Andreasen PA.

Cell Chem Biol. 2016 Jun 23;23(6):700-8. doi: 10.1016/j.chembiol.2016.04.013. Epub 2016 Jun 2.

12.

A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.

Kromann-Hansen T, Oldenburg E, Yung KW, Ghassabeh GH, Muyldermans S, Declerck PJ, Huang M, Andreasen PA, Ngo JC.

J Biol Chem. 2016 Jul 15;291(29):15156-68. doi: 10.1074/jbc.M116.732503. Epub 2016 May 23.

13.

Crystal Structure of a Two-domain Fragment of Hepatocyte Growth Factor Activator Inhibitor-1: FUNCTIONAL INTERACTIONS BETWEEN THE KUNITZ-TYPE INHIBITOR DOMAIN-1 AND THE NEIGHBORING POLYCYSTIC KIDNEY DISEASE-LIKE DOMAIN.

Hong Z, De Meulemeester L, Jacobi A, Pedersen JS, Morth JP, Andreasen PA, Jensen JK.

J Biol Chem. 2016 Jul 1;291(27):14340-55. doi: 10.1074/jbc.M115.707240. Epub 2016 May 6.

14.

Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.

De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N.

EMBO Rep. 2016 Jul;17(7):982-98. doi: 10.15252/embr.201541681. Epub 2016 May 17.

15.

Expected and unexpected features of protein-binding RNA aptamers.

Bjerregaard N, Andreasen PA, Dupont DM.

Wiley Interdiscip Rev RNA. 2016 Nov;7(6):744-757. doi: 10.1002/wrna.1360. Epub 2016 May 12. Review.

PMID:
27173731
16.

Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo.

Botkjaer KA, Kwok HF, Terp MG, Karatt-Vellatt A, Santamaria S, McCafferty J, Andreasen PA, Itoh Y, Ditzel HJ, Murphy G.

Oncotarget. 2016 Mar 29;7(13):16773-92. doi: 10.18632/oncotarget.7780.

17.

Building a Molecular Trap for a Serine Protease from Aptamer and Peptide Modules.

Dupont DM, Bjerregaard N, Verpaalen B, Andreasen PA, Jensen JK.

Bioconjug Chem. 2016 Apr 20;27(4):918-26. doi: 10.1021/acs.bioconjchem.6b00007. Epub 2016 Mar 11.

PMID:
26926041
18.

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.

Gong L, Liu M, Zeng T, Shi X, Yuan C, Andreasen PA, Huang M.

Data Brief. 2016 Jan 6;6:550-5. doi: 10.1016/j.dib.2015.12.050. eCollection 2016 Mar.

19.

Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.

Jiang L, Andersen LM, Andreasen PA, Chen L, Huang M.

Biochim Biophys Acta. 2016 Mar;1860(3):599-606. doi: 10.1016/j.bbagen.2015.12.009. Epub 2015 Dec 12.

PMID:
26691138
20.

Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.

Xu P, Xu M, Jiang L, Yang Q, Luo Z, Dauter Z, Huang M, Andreasen PA.

J Med Chem. 2015 Nov 25;58(22):8868-76. doi: 10.1021/acs.jmedchem.5b01128. Epub 2015 Nov 12.

PMID:
26536069
21.

Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.

Gong L, Liu M, Zeng T, Shi X, Yuan C, Andreasen PA, Huang M.

J Biol Chem. 2015 Oct 23;290(43):25795-804. doi: 10.1074/jbc.M115.677567. Epub 2015 Aug 31.

22.

Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.

Sørensen HP, Xu P, Jiang L, Kromann-Hansen T, Jensen KJ, Huang M, Andreasen PA.

J Mol Biol. 2015 Sep 25;427(19):3110-22. doi: 10.1016/j.jmb.2015.08.005. Epub 2015 Aug 14.

PMID:
26281711
23.

Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools.

Dupont DM, Larsen N, Jensen JK, Andreasen PA, Kjems J.

Nucleic Acids Res. 2015 Dec 2;43(21):e139. doi: 10.1093/nar/gkv700. Epub 2015 Jul 10.

24.

Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.

Bjerregaard N, Bøtkjær KA, Helsen N, Andreasen PA, Dupont DM.

Thromb Haemost. 2015 Jul;114(1):139-49. doi: 10.1160/TH14-08-0686. Epub 2015 Apr 9.

PMID:
25855589
25.

Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.

Dupont DM, Thuesen CK, Bøtkjær KA, Behrens MA, Dam K, Sørensen HP, Pedersen JS, Ploug M, Jensen JK, Andreasen PA.

PLoS One. 2015 Mar 20;10(3):e0119207. doi: 10.1371/journal.pone.0119207. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0126782.

26.

Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.

Jiang L, Zhao B, Xu P, Sørensen HP, Jensen JK, Christensen A, Hosseini M, Nielsen NC, Jensen KJ, Andreasen PA, Huang M.

Int J Biochem Cell Biol. 2015 May;62:88-92. doi: 10.1016/j.biocel.2015.02.016. Epub 2015 Mar 2.

PMID:
25744057
27.

A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.

Zhao B, Xu P, Jiang L, Paaske B, Kromann-Hansen T, Jensen JK, Sørensen HP, Liu Z, Nielsen JT, Christensen A, Hosseini M, Sørensen KK, Nielsen NC, Jensen KJ, Huang M, Andreasen PA.

PLoS One. 2014 Dec 29;9(12):e115872. doi: 10.1371/journal.pone.0115872. eCollection 2014.

28.

The solution structure of the MANEC-type domain from hepatocyte growth factor activator inhibitor-1 reveals an unexpected PAN/apple domain-type fold.

Hong Z, Nowakowski M, Spronk C, Petersen SV, Andreasen PA, Koźmiński W, Mulder FA, Jensen JK.

Biochem J. 2015 Mar 1;466(2):299-309. doi: 10.1042/BJ20141236.

PMID:
25510835
29.

Local transient unfolding of native state PAI-1 associated with serpin metastability.

Trelle MB, Madsen JB, Andreasen PA, Jørgensen TJ.

Angew Chem Int Ed Engl. 2014 Sep 8;53(37):9751-4. doi: 10.1002/anie.201402796. Epub 2014 Jul 22.

PMID:
25049220
30.

Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry.

Trelle MB, Dupont DM, Madsen JB, Andreasen PA, Jørgensen TJ.

ACS Chem Biol. 2014 Jan 17;9(1):174-82. doi: 10.1021/cb400619v. Epub 2013 Nov 14.

PMID:
24138169
31.

Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action.

Roodbeen R, Paaske B, Jiang L, Jensen JK, Christensen A, Nielsen JT, Huang M, Mulder FA, Nielsen NC, Andreasen PA, Jensen KJ.

Chembiochem. 2013 Nov 4;14(16):2179-88. doi: 10.1002/cbic.201300335. Epub 2013 Oct 2.

PMID:
24115455
32.

Three monoclonal antibodies against the serpin protease nexin-1 prevent protease translocation.

Kousted TM, Skjoedt K, Petersen SV, Koch C, Vitved L, Sochalska M, Lacroix C, Andersen LM, Wind T, Andreasen PA, Jensen JK.

Thromb Haemost. 2014 Jan;111(1):29-40. doi: 10.1160/TH13-04-0340. Epub 2013 Oct 2.

PMID:
24085288
33.

Allosteric inactivation of a trypsin-like serine protease by an antibody binding to the 37- and 70-loops.

Kromann-Hansen T, Lund IK, Liu Z, Andreasen PA, Høyer-Hansen G, Sørensen HP.

Biochemistry. 2013 Oct 8;52(40):7114-26. doi: 10.1021/bi400491k. Epub 2013 Sep 30.

PMID:
24079451
34.

Protein conformational change delayed by steric hindrance from an N-linked glycan.

Bager R, Johansen JS, Jensen JK, Stensballe A, Jendroszek A, Buxbom L, Sørensen HP, Andreasen PA.

J Mol Biol. 2013 Aug 23;425(16):2867-77. doi: 10.1016/j.jmb.2013.05.007. Epub 2013 May 20.

PMID:
23702291
35.

Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist.

Lin Z, Jensen JK, Hong Z, Shi X, Hu L, Andreasen PA, Huang M.

Chem Biol. 2013 Feb 21;20(2):253-61. doi: 10.1016/j.chembiol.2013.01.002.

36.

Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].

37.

Rezymogenation of active urokinase induced by an inhibitory antibody.

Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M.

Biochem J. 2013 Jan 1;449(1):161-6. doi: 10.1042/BJ20121132.

PMID:
23016918
38.

Hydrogen/deuterium exchange mass spectrometry reveals specific changes in the local flexibility of plasminogen activator inhibitor 1 upon binding to the somatomedin B domain of vitronectin.

Trelle MB, Hirschberg D, Jansson A, Ploug M, Roepstorff P, Andreasen PA, Jørgensen TJ.

Biochemistry. 2012 Oct 16;51(41):8256-66. doi: 10.1021/bi3008998. Epub 2012 Oct 4.

PMID:
22957734
39.

Interconversion of active and inactive conformations of urokinase-type plasminogen activator.

Liu Z, Kromann-Hansen T, Lund IK, Hosseini M, Jensen KJ, Høyer-Hansen G, Andreasen PA, Sørensen HP.

Biochemistry. 2012 Oct 2;51(39):7804-11. doi: 10.1021/bi3005957. Epub 2012 Sep 19.

PMID:
22950516
40.

Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.

Bager R, Kristensen TK, Jensen JK, Szczur A, Christensen A, Andersen LM, Johansen JS, Larsen N, Baatrup E, Huang M, Ploug M, Andreasen PA.

J Biol Chem. 2012 Aug 10;287(33):27526-36. doi: 10.1074/jbc.M112.369207. Epub 2012 Jun 25.

41.

Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways.

Andersen LM, Andreasen PA, Svendsen I, Keemink J, Østergaard H, Persson E.

J Biol Chem. 2012 Mar 16;287(12):8994-9001. doi: 10.1074/jbc.M111.312330. Epub 2012 Jan 24.

42.

Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, Quigley JP.

Neoplasia. 2011 Sep;13(9):806-21.

43.

Nucleic acid aptamers against proteases.

Dupont DM, Andersen LM, Botkjaer KA, Andreasen PA.

Curr Med Chem. 2011;18(27):4139-51. Review.

PMID:
21838691
44.

The binding mechanism of a peptidic cyclic serine protease inhibitor.

Jiang L, Svane AS, Sørensen HP, Jensen JK, Hosseini M, Chen Z, Weydert C, Nielsen JT, Christensen A, Yuan C, Jensen KJ, Nielsen NC, Malmendal A, Huang M, Andreasen PA.

J Mol Biol. 2011 Sep 16;412(2):235-50. doi: 10.1016/j.jmb.2011.07.028. Epub 2011 Jul 23.

PMID:
21802428
45.

Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.

Hosseini M, Jiang L, Sørensen HP, Jensen JK, Christensen A, Fogh S, Yuan C, Andersen LM, Huang M, Andreasen PA, Jensen KJ.

Mol Pharmacol. 2011 Oct;80(4):585-97. doi: 10.1124/mol.111.072280. Epub 2011 Jun 30.

PMID:
21719463
46.

Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

Jensen JK, Thompson LC, Bucci JC, Nissen P, Gettins PG, Peterson CB, Andreasen PA, Morth JP.

J Biol Chem. 2011 Aug 26;286(34):29709-17. doi: 10.1074/jbc.M111.236554. Epub 2011 Jun 21.

47.

Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.

Behrens MA, Botkjaer KA, Goswami S, Oliveira CL, Jensen JK, Schar CR, Declerck PJ, Peterson CB, Andreasen PA, Pedersen JS.

J Mol Biol. 2011 Aug 12;411(2):417-29. doi: 10.1016/j.jmb.2011.05.026. Epub 2011 Jun 6.

PMID:
21669207
48.

Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Botkjaer KA, Fogh S, Bekes EC, Chen Z, Blouse GE, Jensen JM, Mortensen KK, Huang M, Deryugina E, Quigley JP, Declerck PJ, Andreasen PA.

Biochem J. 2011 Aug 15;438(1):39-51. doi: 10.1042/BJ20110129.

49.

DNA Methylation Profiles of Protease Nexin 1 (SERPINE2) Gene in Human Cell Lines.

Gao S, Andreasen PA.

Chin J Cancer Res. 2011 Jun;23(2):92-8. doi: 10.1007/s11670-011-0092-5.

50.

Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.

Lin Z, Jiang L, Yuan C, Jensen JK, Zhang X, Luo Z, Furie BC, Furie B, Andreasen PA, Huang M.

J Biol Chem. 2011 Mar 4;286(9):7027-32. doi: 10.1074/jbc.M110.204537. Epub 2011 Jan 3.

Supplemental Content

Loading ...
Support Center